What genetic factors are associated with mucous membrane pemphigoid?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Genetics of Mucous Membrane Pemphigoid

*The HLA-DQB10301 allele is the most strongly established genetic risk factor for mucous membrane pemphigoid, conferring substantial disease susceptibility across all clinical subtypes, with additional contributions from HLA-DRB111 (particularly the 1101 subtype), HLA-DQA10505, and the recently identified GALC gene polymorphisms.*

Primary HLA Associations

The genetic architecture of MMP centers predominantly on HLA class II alleles:

HLA-DQB1*0301

  • This allele shows the strongest and most consistent association with MMP, present in approximately 96% of patients versus 48% of controls 1
  • Confers a relative risk of 5.25 for MMP specifically, compared to 2.22 for bullous pemphigoid 2
  • Associated with all clinical sites of involvement (oral, ocular, skin, nasal, genital, pharyngeal) with the exception of laryngeal, esophageal, and perianal sites 1
  • Critically, this allele correlates with the production of circulating anti-basement membrane IgG antibodies, suggesting a mechanistic role in T-cell recognition of basement membrane antigens 1
  • Homozygosity for DQB1*0301 occurs in 43% of MMP patients versus only 8% of controls, further amplifying disease risk 3

HLA-DRB1*11 and Subtypes

  • The DRB1*11 allele demonstrates significant association with pemphigoid diseases 2
  • The DRB1*1101 subtype specifically shows strong correlation with increased disease risk 2
  • The risk conferred by DRB1*1101 is significantly higher in drug-induced bullous pemphigoid (particularly dipeptidyl peptidase-4 inhibitor-induced disease) compared to idiopathic MMP 2

HLA-DQA1*0505

  • This allele is significantly associated with increased pemphigoid risk 2
  • Like DRB1*1101, shows stronger associations in drug-induced variants 2

Protective Alleles

  • HLA-DQA1*0201 appears to confer protection against pemphigoid development (OR 0.3), with no heterogeneity across studies 2

HLA Haplotypes

Beyond individual alleles, specific haplotype combinations amplify risk:

  • DRB11101-DQB10301 haplotype: Significantly associated with increased pemphigoid risk 2
  • DRB111-DQA105-DQB1*0301 haplotype: Shows strong disease association 2
  • DRB104-DQB10301 haplotype: Also demonstrates increased frequency in patients 1

Non-HLA Genetic Factors

GALC Gene

A genome-wide association study identified the β-galactocerebrosidase gene (GALC) on chromosome 14 as a novel susceptibility locus 4:

  • SNP rs17203398 (located intronically in GALC) shows an odds ratio of 3.9 for MMP 4
  • This finding was independently replicated in a separate German cohort 4
  • Suggests β-galactocerebrosidase may play a pathogenic role in MMP development, though functional mechanisms require further investigation 4

CASC16-CHD9 Intergenic Region

  • Recessive polymorphisms in rs9936045 (chromosome 16, between CASC16 and CHD9) show an odds ratio of 3.1 4
  • These polymorphisms may impact neighboring gene activity and facilitate MMP emergence 4

Cytokine Gene Polymorphisms

  • IL-4 receptor A (IL-4RA) polymorphism: The allele A at position -1902 is significantly more frequent in oral pemphigoid patients 5
  • The A/A genotype (present in 90% of oral pemphigoid patients) is associated with reduced IL-4 response 5
  • This may partially explain the lower likelihood of scarring in oral-predominant disease, given IL-4's role in fibrotic processes 5

Clinical Implications

Subtype-Specific Associations

The genetic predisposition shows some variation by clinical presentation:

  • Oral-predominant MMP: Strong DQB1*0301 association (95% of patients) 3
  • Ocular involvement: Positive trend toward increased DQB1*0301 expression, potentially correlating with disease severity 1
  • Drug-induced pemphigoid: Significantly stronger associations with DRB11101 and DQA10505 compared to idiopathic disease 2

Pathogenic Mechanisms

The genetic data suggest that:

  • HLA-DQB1*0301 likely facilitates T-cell recognition of basement membrane antigens, driving IgG autoantibody production 1
  • The consistent association across multiple clinical sites indicates a shared immunopathogenic pathway despite phenotypic heterogeneity
  • Non-HLA genes (GALC, IL-4RA) may modulate disease expression and severity rather than primary susceptibility

Important Caveats

  • No HLA class I associations have been identified, indicating the pathogenesis is primarily driven by class II-mediated antigen presentation 1
  • While genetic factors are important, they are not deterministic—environmental triggers and other factors clearly contribute to disease development
  • The rarity of MMP limits the power of genetic studies, and larger cohorts are needed to identify additional susceptibility loci

References

Related Questions

How should I manage a patient with a 20‑year history of bullous skin lesions that rupture and form erosions, now presenting with extensive erosions on the back of the chest?
What are the recommended azathioprine dosing, monitoring, and safety guidelines for treating adult pemphigus vulgaris?
What are the causes and treatment options for bullous pemphigoid?
What is the appropriate management for debility caused by mucous membrane pemphigoid (MMP)?
What dermatologic diseases are associated with the HLA‑DQB1*0301 allele?
In patients with acute abdominal pain, what findings can ultrasound (US) detect that computed tomography (CT) may miss?
What intramuscular olanzapine (generic) backup dose should be given to match a patient's oral maintenance dose, using standard IM strengths and respecting the limits of 10 mg per administration and 20 mg total daily, and how should the dose be adjusted for elderly patients, hepatic impairment, or concomitant CNS depressants?
What intramuscular (IM) backup dose of olanzapine should be given to an adult patient already taking 10 mg orally?
What illnesses are associated with the HLA‑DQB1*0301 allele?
Can I take lazertinib while amivantamab is on hold because of extreme fatigue?
What is the recommended dosing, contraindications, and alternative muscle relaxants for methocarbamol (Robaxin)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.